Joshua McClure is CEO, Co-founder, and Co-inventor of Maxwell Biosciences, a preclinical drug platform company that develops biomimetic therapeutics – synthetic compounds that mimic and improve upon biomolecules. Today he discusses Maxwell’s first-in-class, CLAROMER™ brand drug platform that has been shown to be effective in destroying viruses, bacteria, fungi, and some cancers, while safely avoiding healthy cells. The compounds imitate key components of the immune system, humanity’s greatest asset in fighting disease. 

A graduate of the United States Air Force Academy, Joshua has over 20 years of experience as a CEO. He is a multi-patent innovator with a background in military and commercial intelligence and now devotes his time to biotechnologies. His knowledge of leadership principles alongside his 2016 big data study of immune proteins’ impact on health outcomes are the foundation of the company.

In 2015, Joshua dedicated himself to combating pathogens – the leading cause of human disease and mortality. He co-invented the world’s first tissue-safe virucidal anti-infectives, anti-infective device coatings, the first antiviral condom, human gene expression modulation technology, geo-placed digital media, facial recognition-based commerce, and designed and commercialized the world’s first dual core laptop computer in partnership with Advanced Micro Devices.

Prior to Maxwell, Joshua was the CEO and founder ​of RealMassive, the real estate industry’s largest source of commercial property data.

Liked it? Take a second to support healthprofessionalradio on Patreon!